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Todeterminethediagnosticutilityofserumcalprotectin,amediatorofinnateimmuneresponseagainstinfections,weperformeda
multicenter study involving newborns with a birth weight < 1500g and a postnatal age > 72 hours of life. The diagnostic accuracy
of serum calprotectin was compared with that of the most commonly used markers of neonatal sepsis (white blood cell count,
immature-to-total-neutrophil ratio, platelet count, and C-reactive protein). We found that the serum calprotectin concentration
was signiﬁcantly higher (P<. 001) in 62 newborns with conﬁrmed sepsis (3.1±1.0 µg/mL) than in either 29 noninfected subjects
(1.1±0.3µg/ml) or 110 healthy controls (0.91±0.58µg/ml). The diagnostic accuracy of serum calprotectin was greater (sensitivity
89%, speciﬁcity 96%) than that of the traditional markers of sepsis. In conclusion, serum calprotectin is an accurate marker of
sepsis in very low birth weight newborns.
1.Introduction
The neonatal immune response to many pathogens is largely
immature [1]. At this age, infections are characterized by a
high mortality and morbidity [2, 3]. An early diagnosis is
crucial because the clinical course may be fulminating, par-
ticularly in very low birth weight (VLBW) babies, in whom
the onset is often inconspicuous, with minimal, subtle, and
nonspeciﬁc signs [1–3] .I s o l a t i o no fb a c t e r i af r o mc e n t r a l
body ﬂuid (usually blood) is the standard test for neonatal
systemic infection; however, the result of culture is not
available before 24–48h and is negative in many instances,
even in cases of a clear clinical picture of sepsis [4–6].
Neonatal septicaemia is associated with hyperinﬂam-
matory host responses that subtend activation of immune
system. A broad spectrum of inﬂammatory markers has
been proposed for the diagnosis of neonatal sepsis [4].
However, most of these markers are mediators of an
acquired immunity response, which is largely immature in
the neonatal period [4]. On the contrary, innate immunity
is fully developed in the ﬁrst weeks of life, but the potential
diagnostic role of components of innate immunity has not
been investigated [7, 8].
Calprotectin (aka MRP8/14, calgranulin, cystic ﬁbrosis-
associated antigen, and S100), a major product of innate
immunity cells, is an antimicrobial peptide that protects
cells against invasive microorganisms and regulates adhesion
of leukocytes to the endothelium and extracellular matrix
during the inﬂammatory process [4, 9]. Calprotectin is
released by innate immunity cells immediately after host-
pathogen interaction [9] and is detectable in body ﬂuids by
means of a simple ELISA technique [10, 11].
Calprotectin has been proposed for the diagnosis of
many inﬂammatory conditions [9]. However, its use in the2 Clinical and Developmental Immunology
diagnosis of neonatal sepsis remains unexplored. The aim of
this study was to investigate the diagnostic power of serum
calprotectin (SC) measurement in VLBW infants with sepsis.
2.MaterialsandMethods
This prospective investigation involved 3 Neonatal Intensive
Care Units (NICUs) in the south of Italy over a 24-month
enrolment study period. The study protocol was approved
by the Ethics Committee of each center. Written informed
consent was obtained from the parents of all infants enrolled
in the study. The research was not sponsored by any
company.
Newborns were eligible for the study when they fulﬁlled
all of the following criteria: (1) gestational age > 24 weeks;
(2) birth body weight (BW) < 1500g; (3) postnatal age >
72 hours; (4) no antibiotic treatment for at least 2 weeks
before enrolment; (5) parental consent. Infants with the
following conditions were excluded: (1) Apgar score < 3a t
5min; (2) critical clinical conditions, as indicated by a blood
pH < 6.8, or by the presence of hypoxia with persistent
bradycardia; (3) incomplete clinical data or deviation from
the study protocol; (4) maternal history of immunologic,
inﬂammatory, or infectious diseases requiring antibiotic
therapy during pregnancy, including the labour/delivery
process;(5)surgery;(6)intraventricularhaemorrhagegrades
III-IV [12]. Enrolled subjects were prospectively divided into
2 groups according to the presence or absence of features
suggestive of sepsis.
According to standardized criteria [4, 5, 13, 14], systemic
infection was suspected in the presence of ≥ 2 of the follow-
ing clinical features: poor perfusion (capillary reﬁlling > 3
seconds), muscle hypotonia or hypertonia, lethargy, enteral
nutrition intolerance, bloody stools, progressive increase in
O2 requirement, bradycardia, unstable body temperature,
unexplained and persistent metabolic acidosis (base deﬁcit
> 10mmol/L), and/or hyperglycaemia (>10mmol/L). White
bloodcellcount(WBC),immature-to-total-neutrophil(I/T)
ratio, platelet count, serum C-reactive protein (CRP), cul-
tures of blood, urine, and endotracheal aspirate (when
patient was intubated) for bacteria and fungi, chest or
abdominal radiograph if the patient presented signs sug-
gestive of thoracic or intra-abdominal disease, cardiac and
brain ultrasonography, electroencephalography (EEG), and
screening tests for metabolic diseases were performed in all
subjects with suspected sepsis.
According to previously standardized criteria [5, 13,
15, 16] we divided the patients into (1) a septic group,
constituted by infants with suspected episodes of sepsis
that had been conﬁrmed as systemic infection by positive
cultures (culture-proven sepsis) or by the presence of a
typical clinical picture of sepsis associated with at least one
positive traditional laboratory marker of infection and a
clear improvement after a full course of antibiotic therapy
(high probable sepsis); (2) a nonseptic group, constituted
by infants who met the initial criteria for suspected sepsis
but were subsequently classiﬁed as being noninfected and
had a deﬁnitive diagnosis unrelated to sepsis, or of neonates
in whom symptoms disappeared without antibiotic therapy
within 8 hours.
Blood samples for SC determination were collected
within 60min of the onset of symptoms. For comparison,
blood specimens were collected during routine sampling
to determine SC levels from newborns without symptoms
of sepsis, that is, the control group. The results of SC
measurements were concealed until statistical analysis was
concluded.
2.1. Laboratory Procedures. All laboratory investigations
were performed by researchers unaware of the clinical data.
C o m p l e t eb l o o dc o u n t sw e r ed o n eb yc e l lc o u n t e r[ 17].
Leukocytes were diﬀerentiated by microscopy. The I/T ratio
was calculated as the sum of immature granulocytes divided
by the sum of all neutrophils [17]. The CRP was measured
byratenephelometry[14].Serumcalprotectinwasmeasured
by a commercial ELISA assay (Calprest, Eurospital, Trieste,
Italy) [9–11]. In brief, a blood sample (0.5mL) for serum
calprotectin measurements was collected in blood collection
tubes containing ethylenediaminotetraacetic acid (EDTA).
The sample was centrifuged for 10min at 10000rpm and
the extracted serum was collected and frozen at −20◦C
for subsequent measurement. The serum was diluted 1:50,
and 100µL of each sample was added to the wells of
a plate and incubated at room temperature for 45min.
The plate was then washed 3 times with diluted washing
solution, and 100µL of puriﬁed rabbit anticalprotectin
antibodies conjugated with alkaline phosphatase were added
and incubated for 45min at room temperature. A second
washing procedure was performed, 100µLo fe n z y m es u b -
strate solution was added to each well, and optical density
was read at 405nm. Serum calprotectin concentration was
calculated from the standards and expressed as µg/mL [9–
11]. The minimum concentration of human calprotectin
detected with this kit is 1.6ng/mL.
2.2. Statistical Analysis. The Pearson chi-square test was
performed in the case of categorical variables. Continuous
variables were expressed as mean and 95% conﬁdence (CI).
The groups were compared for variables by the one-way
ANOVA procedure with the Bonferroni test for the posthoc
analysis. After checking for assumptions, linear regression
analysis with a stepwise method was used to study the
possible eﬀect of the diﬀerent variables (BW, gestational age,
sex, age at enrolment, mode of delivery, prenatal steroid
use, WBC, site of infection and pathogen involved, presence
of respiratory distress syndrome, patent ductus arteriosus,
and periventricular leukomalacia) on SC concentration.
Binary logistic regression analysis was performed using as
dependentvariablethepresenceofsepsisandasindependent
variables WBC, I/T ratio, platelet count, CRP, and SC.
All tests of signiﬁcance were two sided. A P value of
≤ .05 was considered signiﬁcant. The optimal cut-oﬀ SC
value to distinguish septic from nonseptic patients among
subjects investigated for suspected sepsis was determined
using receiving operating characteristic (ROC) curve analy-















Figure 1: Levels of serum calprotectin in septic, nonseptic, and
control VLBW newborns.
package for Windows (release 16.0.0; SPSS Inc., Chicago, Ill,
USA) and StatsDirect (release 2.6.6).
3. Results
A total of 231 newborns were eligible for the study. Twenty-
eight were excluded because of incomplete clinical data or
deviationfromthestudyprotocol(10patients),intraventric-
ular haemorrhage (8 patients), critical clinical condition (8
patients), and lack of parental consent (2 patients). Ninety-
threenewborns(35,32,and26,perCenter)wereinvestigated
for suspected sepsis: 62 were classiﬁed as “septic” (52 culture
proven: 12 E. coli, 8 Enterococcus faecalis, 6 Pseudomonas
aeruginosa,6Klebsiella pneumonia, 6 Staphylococcus coag-
ulase negative, 6 Candida albicans, 5 Serratia marcescens, 3
Streptococcus pyogenes, and 10 high probable sepsis), 29 were
included in nonseptic group, and two infants were lost to
followup (transferred to other hospitals). One hundred and
ten infants were enrolled as controls. The main clinical and
demographic characteristics were similar in the three groups
(Table 1).
Serum calprotectin concentration was higher in the
septic group than in the nonseptic and control groups
(Figure 1). Value of CRP was signiﬁcantly diﬀerent between
septic and control group but not between septic and
nonseptic patients (Table 2). The linear regression analysis
demonstrated that SC was not inﬂuenced by BW, gestational
age, sex, age at the enrolment, mode of delivery, prenatal
steroid use, WBC count, site of infection and the oﬀending
pathogen, presence of respiratory distress syndrome, patent
ductus arteriosus, and periventricular leukomalacia.
The optimal cut-oﬀ serum calprotectin value to dis-
tinguish infants with sepsis from infants without sepsis
was 1.7µg/mL as determined by the ROC curve analysis,
characterized by a vast area under curve demonstrating an
excellent discrimination power (Figure 2). At this cut-oﬀ
value, all infants with fungi-related sepsis (n = 6) had SC
levels above normal value, whereas only 2/6 had deranged
values of traditional markers (1 with platelet count > 500.0×
103/mm3; 1 with CRP > 10mg/dL). The diagnostic accuracy




















Figure 2: Receiver operating characteristic curve deﬁning an
optimal serum calprotectin cut-oﬀ value (1.7µg/mL) to distinguish
septic from nonseptic symptomatic patients.
regression analysis showed that SC (OR 164.6; 95% CI 21.6–
1255.1; P<. 001) and CRP (OR 1.1; 95% CI 1.0-1.1; P =
.007) were predictors of sepsis in our population.
4. Discussion
A high sensitivity and negative predictive value, associated
withagoodspeciﬁcityandpositivepredictivevalue,supports
the use of SC in the diagnosis of sepsis in a VLBW newborn.
A limited number of pathogens are responsible for sepsis
among neonates. Most pathogens are encapsulated bacteria
[1]. The immunologic advantage of this capsule is that the
bacteria elude phagocytic killing, because the coating blocks
complement binding and opsonization.
Acute phase proteins, such as CRP [4], and the produc-
tion of antibodies against the polysaccharide promote the
elimination of the pathogens [4]. However, this immune
response takes precious time [1], while antimicrobial pep-
tides are promptly and abundantly released after the host-
pathogen interaction [4, 8, 9].
In this context, SC measurement could overcome many
of the limitations of the most common markers proposed
for the diagnosis of neonatal sepsis, that is, haematological
tests, acute phase proteins, chemokines, cytokines, and
adhesion molecules [4]. Haematological markers have a low
accuracy; moreover, sensitivity and speciﬁcity vary widely
across studies being between 17% and 90% and 31% and
100%, respectively [4, 5, 18, 19]. In our study, WBC count
did not diﬀer signiﬁcantly between septic and nonseptic
VLBW subjects. Diﬀerently, the I/T ratio was higher in
septic patients than in either nonseptic or control subjects.
Unfortunately, the low sensitivity of this marker limits its
use in clinical practice. The most widely used acute phase
reactant for the diagnosis of neonatal sepsis is CRP [4,
18]. However, because the concentration of CRP increases
rather slowly in the initial phase of inﬂammatory response4 Clinical and Developmental Immunology
Table 1: Main demographic and clinical characteristics of the study population.
Septic group Nonseptic group Controls
No. 62 29 110
Birth weight, g 1082 (1029–1135) 1178 (1080–1275) 1088 (1045–1131)
Gestational age, weeks 29.2 (28.7–29.9) 30.1 (29.1–31.1) 29.2 (28.7–29.6)
Male, n (%) 39 (63) 13 (45) 67 (61)
Spontaneous delivery, n (%) 10 (16) 3 (11) 13 (12)
Intubation for respiratory distress syndrome, n (%) 53 (85)∗ 11 (38) 34 (31)
Duration of invasive mechanical ventilation before enrolment 5.8 (6.5–9.7) 4.8 (2.5–7.0) 5.9 (4.5–7.2)
Subjects with central vascular access, n (%) 30 (48) 12 (41) 36 (33)
Age at enrolment, days 8.7 (7.2–10.1) 6.8 (5.5–8.0) 6.9 (6.1–7.7)
Data expressed as mean (95% Conﬁdence Interval for Mean) if not speciﬁed.
∗P<. 001 versus other two groups.
Table 2: Results of laboratory parameters evaluated.
















(10.688–14.076) 1.000 .106 1.000
I/T ratio 0.91 (0.58–1.24) 0.030 (0.01–0.06) 0.042 (0.02–0.06) .025 .025 1.000
Platelet count
(n × 103/mm3) 278 (239–317) 289 (256–322) 259 (237–281) 1.000 1.000 .802
C-reactive protein
(mg/dL) 13.1 (7.4–18.7) 6.2 (0.38–12.8) 2.1 (1.7–2.6) .123 <.001 .591
Serum calprotectin
(µg/mL) 3.1 (2.9–3.4) 1.1 (0.9–1.2) 0.91 (0.8–1.0) <.001 <.001 .515
I/T ratio: immature-to-total-neutrophil ratio.
Data expressed as mean (95% Conﬁdence Interval for Mean) if not speciﬁed.
to pathogens, the sensitivity of CRP testing at the time of
sepsis evaluation is insuﬃcient [4]. Our results conﬁrm this
observation. Moreover, CRP is elevated only in a minority
of infants aﬀected by fungi-related sepsis [4]. Another acute
phase marker is procalcitonin (PCT). Its diagnostic proﬁle
hasbeenclaimedtobesuperiortootheracutephaseproteins,
including CRP. However, serum PCT concentrations are
variable in the ﬁrst few days of life, and very high serum
concentrations of PCT have been detected in patients with
acute lung and inhalation injuries and cardiac diseases,
without evidence of infection [4]. Chemokines, cytokines,
and adhesion molecules have a high diagnostic accuracy
for sepsis, but the lack of adequate technology in many
neonatal intensive care units and high costs have impeded
the widespread use of these markers in clinical practice [4,
14,15,19].Morerecently,aproteomicquantitativeapproach
hasbeenproposedtoidentifybiomarkersforthediagnosisof
sepsis [20]. Despite promising results, the application of pro-
teomic techniques is not feasible in hospital laboratories that
lack speciﬁc facilities. Another limitation of the proposed
proteomic protocol may not diﬀerentiate between proteins
that occur in low concentrations in plasma and that have a
similarmolecularweight,namely,interleukins,antimicrobial
peptides, and chemokines.
We found that SC is an early, accurate, and easy-to-use
marker of neonatal sepsis. When measured upon the appear-
ance of the ﬁrst clinical signs of sepsis, its sensitivity, PPV,
and NPV were higher than those reported for traditional
tests [2–4]. Serum calprotectin levels were not inﬂuenced
by postnatal age, which is another advantage over some
traditional diagnostic tools [4]. The ELISA technique used to
detect SC is simple, rapid, and inexpensive and requires only
a small volume of blood sample thereby reducing the risk of
iatrogenic anaemia [11]. Moreover, the ELISA technique for
SC is now available in a more rapid and less expensive bed-
side test, particularly useful in neonatology [21].
The encouraging results reported herein provide a ratio-
nale for investigations of the role of SC in the management
of sepsis. In particular, it may be worthwhile to assess
the prognostic role of SC as regards the severity of sepsis.
The high NPV of SC suggests that it could be an aid in
therapy decision-making. In this context, the optimal cut-
oﬀ value deﬁned in this study could be useful in further
research in this ﬁeld. Finally, SC could help to resolve the
dilemma of whether to start antibiotics immediately after
sepsis screening and when to stop treatment, but there is a
need for studies speciﬁcally designed to address these issues.
The study has some limitations. Firstly, as reported
in other studies [4, 5, 13–16], some of the patients thatClinical and Developmental Immunology 5
Table 3: Diagnostic accuracy of various markers in identifying septic patients among symptomatic newborns.
Sensitivity Speciﬁcity PPV NPV Likelihood ratio (+ test)
WBC 14 (7–26) 93 (77–99) 82 (48–98) 34 (23–45) 2 (1–8)
I/T ratio 60 (46–72) 82 (64–94) 88 (74–96) 48 (34–64) 3 (2–8)
Platelet count 13 (6–24) 76 (56–90) 53 (27–79) 29 (19–40) 0.5 (0-1)
CRP 29 (18–42) 93 (77–99) 90 (68–99) 38 (27–50) 4 (1–16)
Serum calprotectin 89 (78–95) 96 (82–99) 98 (90–99) 80 (63–92) 26 (5–145)
PPV: positive predictive value. NPV: negative predictive value. WBC: white blood count. CRP: C-reactive protein. I/T ratio: immature-to-total-neutrophil
ratio.
N.B. Cut-oﬀ value: total neutrophil count < 4.0 or > 25.0 × 103/mm3; platelet count < 50.0 or > 500.0 × 103/mm3;I / Tr a t i o> 0.2; CRP >10mg/dL; serum
calprotectin >1.7µg/mL [8–10, 12, 16].
we diagnosed with sepsis had negative microbiological
examinations. Following previous studies, we classiﬁed such
cases as “high probable sepsis”. These infants presented the
typical clinical picture of sepsis associated with positive
traditional laboratory markers of infection. All patients
underwent a clear clinical improvement after a full course of
antibiotic treatment. Thus, it is unlikely that we misclassiﬁed
these patients. Secondly, we studied only VLBW infants and
excluded asphyxia and critical ill subjects. Further research is
needed to investigate the diagnostic accuracy of SC in these
settings.
To conclude, ours is the ﬁrst study to investigate an
innate immunity component as a biomarker of septicaemia
in VLBW infants. Serum calprotectin could be a practical
marker in the diagnostic approach to VLBW infants with
suspected sepsis, and it could open the way to investigations
exploring the role of other components of innate immunity
in the diagnostic workup of neonates with infectious condi-
tions.
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